Kura reports additional Phase II data for tipifarnib in SCCHN

Kura Oncology Inc. (NASDAQ:KURA) reported updated data from six evaluable patients with v-Ha-ras Harvey rat sarcoma viral oncogene homolog (HRAS)-mutant relapsed or refractory squamous cell carcinoma of the

Read the full 284 word article

User Sign In